<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 13, 2000
VIROPHARMA INCORPORATED
-----------------------
(Exact name of issuer as specified in charter)
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on November 14, 2000, ViroPharma Incorporated
announced the appointment of Martin J. Driscoll as vice president, commercial
operations and business development.
This report, including the press release attached hereto, contains forward-
looking statements, including statements relating to the Company's ongoing
efforts to commercialize its product candidates. Certain of ViroPharma's
product candidates, including pleconaril, currently are in clinical trials.
There can be no assurance that planned or ongoing clinical trials can be
successfully concluded or concluded in accordance with the Company's anticipated
schedule. The conduct of clinical trials and acquiring regulatory approval for
investigational pharmaceutical products are subject to risks and uncertainties.
Neither the FDA nor any other regulatory authority has approved pleconaril or
any of ViroPharma's other product candidates for commercialization. There can be
no assurance that FDA or other regulatory authority approval for pleconaril or
any other product candidate under development by ViroPharma will be granted on a
timely basis or at all. Even if approved, there can be no assurance that
pleconaril will achieve market acceptance. These factors, and other factors
that could cause future results to differ materially from the expectations
expressed in this report, including the press release attached hereto, include,
but are not limited to, those described in ViroPharma's most recent Registration
Statement on Form S-3 filed with the Securities and Exchange Commission. The
forward-looking statements contained in this report, including the press release
attached hereto, may become outdated over time. ViroPharma does not assume any
responsibility for updating any forward-looking statements.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated November 14, 2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: November 14, 2000 By: /s/ Michel de Rosen
-------------------
Michel de Rosen
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated November 14, 2000
